Step 1
Decompose
Convert the pitch into the claims that must be true for the deal to work. Rank them by decision importance. Drop claims that do not change the check.
Decision Sprint method
How we pressure-test the science case—and what we will not pretend to know.
You get an inspectable, source-linked map of what must be true for the deal: what holds against published evidence, what conflicts, and what is still unknown. Tempus is a major precision-medicine company that uses biomedical data and knowledge graphs to pressure-test drug-development hypotheses for industry. BioticaBio does the parallel job for investors—graph-backed claim testing plus a human synthesis your partners can inspect. You do not get certainty, a standing diligence function, or a substitute for specialist counsel.
Four steps
Step 2
Check the evidence
Test each material claim against published literature, trials, targets, labels, patents, and known failure modes—looking for support and contradiction, not confirmation bias.
Step 3
Integrate
Connect technical findings to timeline, capital, and financing consequences. Domain findings become investment implications your partners can use.
Step 4
Decide
State what holds, what conflicts, and what evidence would change the view. Deliver a brief, memo, and partner briefing with sources attached.
What the evidence graph contributes
- Published literature and trial precedents for the modality and indication
- Target, mechanism, and competitive-class context
- Regulatory labels and public failure modes that inform the thesis
- Patent and prior-art signals as diligence context—not legal opinions
Evidence rubric
- Support: observation that strengthens the claim, with limitation noted.
- Contradiction: conflicting evidence or failed analogue, with comparability note.
- Missing: what could not be established and why it matters to the decision.
- Implication: scientific, time/capital, question, and decision trigger.
Inference policy
Inference is allowed when labeled. Material conclusions link to a source, a calculation, or an explicit inference. Unknown is an answer.
Quality controls
A senior human reviewer owns final synthesis. The graph informs and stresses the thesis; it does not write the investment conclusion. Unreviewed domains are listed.
Scoped-domain policy
Domains outside the signed scope are unreviewed. The sprint can be fast or deep. It cannot honestly be both.
Why lean teams use this instead of a network diligence menu
Network firms sell matched expertise and broad coverage. We sell a claim test against the biomedical evidence graph: decompose the thesis, seek support and contradiction, label missing evidence, and turn each material finding into a decision trigger—sized to one live deal.
Worked examples live in the decision catalogue.
What this is not
BioticaBio does not provide legal opinions, regulatory sign-off, FTO, valuation models, patient-level reanalysis, or investment recommendations. BioticaBio is not affiliated with Tempus and is not a clinical real-world-evidence platform. We do not use “de-risked,” “probability of success,” or “institutional-grade” unless scope and controls justify the words.